Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arcutis Biotherapeutics stock | $26.35

Learn how to easily invest in Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics, Inc
-$0.32 (-1.35%)

Arcutis Biotherapeutics, Inc is a biotechnology business based in the US. Arcutis Biotherapeutics shares (ARQT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcutis Biotherapeutics employs 75 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Arcutis Biotherapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARQT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Arcutis Biotherapeutics stock price (NASDAQ: ARQT)

Use our graph to track the performance of ARQT stocks over time.

Arcutis Biotherapeutics shares at a glance

Information last updated 2021-07-28.
Latest market close$26.35
52-week range$17.51 - $38.49
50-day moving average $26.51
200-day moving average $29.17
Wall St. target price$55.13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.15

Buy Arcutis Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arcutis Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcutis Biotherapeutics price performance over time

Historical closes compared with the close of $26.35 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) 26.35
3 months (2021-04-30) -21.34%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Arcutis Biotherapeutics financials

Gross profit TTM $0
Return on assets TTM -25.26%
Return on equity TTM -41.48%
Profit margin 0%
Book value $9.04
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting Arcutis Biotherapeutics shares

There are currently 2.3 million Arcutis Biotherapeutics shares held short by investors – that's known as Arcutis Biotherapeutics's "short interest". This figure is 0.2% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting Arcutis Biotherapeutics shares can be evaluated.

Arcutis Biotherapeutics's "short interest ratio" (SIR)

Arcutis Biotherapeutics's "short interest ratio" (SIR) is the quantity of Arcutis Biotherapeutics shares currently shorted divided by the average quantity of Arcutis Biotherapeutics shares traded daily (recently around 223130.83743842). Arcutis Biotherapeutics's SIR currently stands at 10.15. In other words for every 100,000 Arcutis Biotherapeutics shares traded daily on the market, roughly 10150 shares are currently held short.

However Arcutis Biotherapeutics's short interest can also be evaluated against the total number of Arcutis Biotherapeutics shares, or, against the total number of tradable Arcutis Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcutis Biotherapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Arcutis Biotherapeutics shares in existence, roughly 50 shares are currently held short) or 0.077% of the tradable shares (for every 100,000 tradable Arcutis Biotherapeutics shares, roughly 77 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Arcutis Biotherapeutics.

Find out more about how you can short Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics share dividends

We're not expecting Arcutis Biotherapeutics to pay a dividend over the next 12 months.

Arcutis Biotherapeutics overview

Arcutis Biotherapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.

Stocks similar to Arcutis Biotherapeutics

Frequently asked questions

What percentage of Arcutis Biotherapeutics is owned by insiders or institutions?
Currently 4.976% of Arcutis Biotherapeutics shares are held by insiders and 89.608% by institutions.
How many people work for Arcutis Biotherapeutics?
Latest data suggests 75 work at Arcutis Biotherapeutics.
When does the fiscal year end for Arcutis Biotherapeutics?
Arcutis Biotherapeutics's fiscal year ends in December.
Where is Arcutis Biotherapeutics based?
Arcutis Biotherapeutics's address is: 3027 Townsgate Road, Westlake Village, CA, United States, 91361
What is Arcutis Biotherapeutics's ISIN number?
Arcutis Biotherapeutics's international securities identification number is: US03969K1088
What is Arcutis Biotherapeutics's CUSIP number?
Arcutis Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 03969K108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site